MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE MARCH 19, 2020 MEETING

DUR Board Roster: State Fiscal Year 2020 (July 1, 2019- June 30, 2020)	May 2019	Sep 2019	Dec 2019	Mar 2020
Lauren Bloodworth, PharmD	✓	✓	✓	✓
Beverly Bryant, MD		✓	✓	✓
Rhonda Dunaway, RPh	✓	✓	✓	
Tanya Fitts, MD	✓		✓	✓
Ray Montalvo, MD (Chair)		✓	✓	✓
Holly Moore, PharmD	✓	✓	✓	✓
Janet Ricks, DO	✓			✓
Dennis Smith, RPh	✓	✓	✓	✓
Cheryl Sudduth, RPh	NA	✓	✓	
James Taylor, PharmD	✓	✓		✓
Alan Torrey, MD	NA	✓		✓
Veda Vedanarayanan, MD	✓	✓		
TOTAL PRESENT	**8***	**10**	**8**	**9**

** Total Present may not be reflected by individual members marked as present above due to members whose terms expired being removed from the list.*

Also Present:

Division of Medicaid (DOM) Staff:
Terri Kirby, RPh, CPM, Pharmacy Director; Cindy Noble, PharmD, MPH, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Carlos Latorre, MD, Medical Director;

University of Mississippi School of Pharmacy - MS-DUR Staff:
Eric Pittman, PharmD, MS-DUR Project Director; Kaustuv Bhattacharya, PhD, Research Assistant Professor - CPMM; Sujith Ramachandran, PhD, Assistant Director – CPMM; Yiran Rong, MS, Research Analyst – MS-DUR;

Conduent Staff:
Lew Anne Snow, RN, BSN, Pharmacy Services Sr. Analyst, Mississippi Medicaid Project; Leslie Leon, PharmD, Clinical Pharmacist, Mississippi Medicaid Project;

Change Healthcare Staff:
Paige Clayton, PharmD, On-Site Clinical Pharmacist; Shannon Hardwick, RPh, CPC Pharmacist; Sarah Boydstun, PharmD, PA Pharmacist;

Alliant Health Staff:
Buddy Ogletree, PharmD, Clinical Pharmacist;

Coordinated Care Organization (CCO) Staff:
Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Mike Todaro, PharmD, Vice President Pharmacy Operations, Magnolia Health; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare; Joseph Vazhappilly, PharmD, MBA, Associate Vice President, Pharmacy Services, Molina Healthcare;

Visitors:
Kevin Aholt, Neurelis Pharmaceuticals; Brian Berhow, Sunovion; Kimberly Clark, ViiV; Scott Farris, Amgen; Phil Hecht, Abbvie; Hope Ladner, The Clay Firm; Chris Lauhoff, Genentech; Nole Mangine, Allergan; Mike Peoples, Lilly; Maria Porter, Actelion Pharmaceuticals; Sonya Powell, Janssen; Michelle Shirley, Indivior; Tracy Smalley, Amgen; Cindy Snyder, Viiv; Joseph Sturgeon, Azurity; Bruce Wallace, Azurity; Doug Welch, Merck; Wendy Williams, Supernaus; Brent Young, Global Blood Therapeutics;

Call to Order:
Dr. Pittman called the meeting to order at 1:05pm and welcomed everyone to the meeting via Zoom.

COVID-19 Update:
Dr. Latorre, Medicaid Medical Director, provided the Board with an update on the status of COVID-19 in MS and Medicaid's response.

OLD BUSINESS:

Dr. Bloodworth moved to approve the minutes from the December 2019 DUR Board Meeting, seconded by Dr. Bryant, and unanimously approved by the DUR Board.

Resource Utilization Review:
Dr. Pittman presented the resource utilization report for October 2019 – December 2019. No abnormal shifts in drug categories were noted.

Feedback and Discussion from Board:
Dr. Pittman shared with the Board a manuscript that resulted from collaborative work between Medicaid and the University of Mississippi that was recently published in Vaccine entitled, "Factors Influencing Human Papillomavirus (HPV) Vaccination Series Completion in Mississippi Medicaid." Dr. Pittman recognized MS-DUR analyst, Sushmitha Inguva, for her work as first author on this project.

NEW BUSINESS:

Update on MS-DUR Educational Interventions:
Dr. Pittman provided an overview of all DUR mailings that occurred December 2019 – February 2020. He pointed out the downward trend in the number of beneficiaries classified as provider shopping. He also provided the Board with copies of the metformin provider education that was released in December 2019 based on recommendations from the DUR Board. The March Medicaid Provider Bulletin will include an article detailing HPV vaccination recommendations based on recommendations by the DUR Board.

Dr. Pittman also presented the Board with a draft version of a tricyclic antidepressant (TCA) provider education letter that will be distributed. This letter will be mailed prior to Medicaid implementing a minimum age edit for the prescribing of TCAs. The Board recommended a minor addition to the letter. This recommendation will be incorporated into the final version, and letters will be mailed beginning April 2020 with the anticipated minimum age edit becoming effective July 1, 2020.

Special Analysis Projects:
Antiretroviral Adherence in the Treatment of HIV
Dr. Pittman presented a report on the adherence to antiretroviral therapies for the treatment of HIV. Adherence to antiretroviral therapy (ART) has been found to be critical to achieving viral load suppression and preventing progression to AIDS. A minimum adherence goal of 90% is recommended by the World Health Organization. Analysis using Pharmacy Quality Alliance's Proportion of Days Covered: Antiretroviral Medications Measure (PDC-ARV-2019) revealed only 42.1% of Medicaid beneficiaries achieved PDC $\geq$ 90% during the study period of calendar year 2019. The PQA measure included patients 18 years and older. The Board recommended MS-DUR expand the analysis to include those younger than 18 years taking ART. Following discussion by the Board, the subsequent recommendations were presented:

1. DOM to collaborate with MSDH, UMMC Infectious Disease Department, and state medical/pharmacy/nursing associations on ART adherence issues.

2. DOM to conduct targeted outreach to providers:
    a. Commend providers having patients with PDCs $\geq$ 90 and seek guidance on best practices;
    b. Educate providers with patients having PDCs < 90.

3. Expand analysis to include beneficiaries less than 18 years. Educational mailings will include providers treating patients less than 18 years.

Dr. Montalvo motioned to approve the recommendations, seconded by Dr. Fitts, and unanimously approved by the Board.

Atrial Fibrillation and Potential Gaps in Care

Dr. Pittman presented a report detailing potential gaps in care for patients diagnosed with atrial fibrillation (Afib). Afib-affected individuals are at increased risk of stroke, and the use of oral anticoagulants serves as a major modifiable protective factor against stroke in patients living with Afib. In the selection of appropriate candidates for thromboembolic prophylaxis, emphasis is placed on balancing risks and benefits. Using the CHA_2DS_2VASC risk assessment criteria, MS-DUR identified Medicaid beneficiaries with Afib diagnosis, high CHA_2DS_2VASC score ($\geq$ 3 females; $\geq$2 males), and no prior bleeding events as potential candidates for anticoagulant drug therapy. Among those beneficiaries, anticoagulant drug utilization during the study period was determined. Following a robust discussion, the subsequent recommendation was presented:

1. DOM should implement an educational intervention notifying prescribers of those beneficiaries diagnosed with Afib that are potential candidates for anticoagulant therapy.

Dr. Montalvo motioned to approve the recommendations, seconded by Dr. Bryant, and unanimously approved by the Board.

An Update to DUR Recommendations for Proton Pump Inhibitor Deprescribing in Mississippi Medicaid

During the March 2018 DUR Board meeting the use of proton pump inhibitors (PPIs) in the Medicaid population was reviewed examining the potential of deprescribing these products. The Board recommended the implementation of a maximum days supply edit of 90 days in a 12-month period for the use of PPIs based on diagnosis. Due to the prioritized implementation of opioid criteria, the implementation of the PPI maximum days supply edit was postponed. At this time the Division of Medicaid requested the DUR Board reevaluate the previous DUR recommendations based on a review of current literature regarding PPI chronic therapy and evaluation of current prescribing trends in Medicaid. Following presentation of an updated DUR analysis and robust discussion, the DUR Board was asked to reaffirm the recommendations from the March 2018 DUR Board meeting or alter those recommendations. The recommendations were as follows:

1. DOM should set an electronic PA edit to limit the maximum days supply for PPI therapy to 90 days in a 12 month period before a PA is required.

2. For therapy exceeding the 90 day limit, DOM should implement electronic or manual PA requirements for the maximum number of days supply based on diagnoses.

3. MS-DUR should implement an educational initiative notifying providers of the new PPI prescribing criteria and guidance on deprescribing.

Dr. Montalvo motioned to approve the recommendations, seconded by Dr. Fitts, and unanimously approved by the Board.

FDA Drug Safety Updates:
Dr. Pittman presented FDA drug safety communications for December 2019 – March 2020.

Pharmacy Program Update:
At this time, the upcoming Pharmacy and Therapeutics Committee is still scheduled for May 12, 2020. Ms. Kirby informed the DUR Board that the state plan amendment (SPA) in response to the SUPPORT Act was approved by CMS. Ms. Kirby also informed the Board that DOM is holding discussions regarding lifting early prescription refill edits during COVID-19. She encouraged pharmacists to monitor DOM social media accounts for notification of changes that may occur.

Miscellaneous:
2020 Meeting Dates/Times
June 11, 2020
September 17, 2020
December 3, 2020
**Meeting times will remain at 1 pm for the next year.*

Next Meeting Information:
Dr. Pittman announced that the next meeting of the DUR Board will take place on June 11, 2020 at 1pm.

Dr. Montalvo motioned to adjourn the meeting at 2:40 pm, seconded by Dr. Bloodworth, and unanimously approved by the Board.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

Announcement concerning the March 19, 2020 Drug Utilization Review (DUR) Board Meeting:

In response to the coronavirus outbreak, the Mississippi Division of Medicaid has changed the March 19, 2020 DUR meeting format.

This meeting will be held as a **virtual meeting for DUR Board members, DOM staff and the public**. It will not take place in Room 145 of the Woolfolk Building.

Participants wishing to attend the virtual meeting can attend by visiting the following link: https://zoom.us/j/749765662?pwd=YVBjdldSK0Jrb0duQW9taWxXVEtOdz09 .

Meeting ID: 749 765 662
Password: 307489

Dial by your location

1-312-626-6799 US (Chicago)

1-929-436-2866 US (New York)

General public attending is asked to please mute audio and disable video connections. When logging into the Zoom meeting, participants must enter their name and company, e.g. John Smith - Company.

Pursuant to DUR bylaws, comments and questions from both industry and the general public will not be allowed during the meeting.